Drugs / Atumelnant
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07570082 | May → Dec 2026 expected | — | Crinetics Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07221084 | Oct 2025 → Feb 2026 | — | Crinetics Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06048887 | Dec 2020 → Apr 2022 | — | Crinetics Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05804669 | Oct 2023 → Oct 2026 expected | ACTH-dependent Cushing syndrome, ectopic ACTH secretion syndrome | Crinetics Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06712823 | Feb 2025 → Jul 2029 expected | classic congenital adrenal hyperplasia | Crinetics Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05907291 | Jul 2023 → Aug 2025 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Crinetics Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07159841 | Jan 2026 → Mar 2030 expected | classic congenital adrenal hyperplasia | Crinetics Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07144163 | Dec 2025 → May 2027 expected | classic congenital adrenal hyperplasia | Crinetics Pharmaceuticals Inc. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atumelnant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07144163 ↗ |
| Known as | CRN04894 | “The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).” NCT06712823 ↗3“associated with atumelnant (also known as CRN04894)” NCT05804669 ↗ “atumelnant (CRN04894)” NCT05907291 ↗ |
| Action | Inhibit | “antagonizes the action of ACTH at its receptor” NCT05804669 ↗ |
| Modality | Small molecule | “Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.” NCT05907291 ↗ |
| Route | Oral | “administered as oral tablets” NCT05804669 ↗ |
| Target | MC2R | “CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.” NCT06048887 ↗ |